An Efficacy And Safety Study Of Tanezumab For The Treatment Of Pain Associated With Chronic Abacterial Prostatitis
NCT ID: NCT00826514
Last Updated: 2021-05-13
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
62 participants
INTERVENTIONAL
2009-03-25
2010-03-17
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of AQX-1125 in Subjects With Chronic Prostatitis/Chronic Pelvic Pain Syndrome
NCT03500159
An Open-Label Study of CC-10004 for Chronic Prostatitis/Chronic Pelvic Pain Syndrome
NCT00701311
Treatment of Chronic Prostatitis/ Pelvic Pain Syndrome With Low-intensity Extracorporeal Shockwave Therapy
NCT04014036
Repeating LiST for Refractory Non-bacterial Prostatitis/Pelvic Pain Syndrome
NCT05366517
The Efficacy and Safety of OM-89 in Patients With Recurrent Chronic Prostatitis/Chronic Pelvic Pain Syndrome
NCT06345014
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tanezumab
Tanezumab
Intravenous, 20 mg, single dose.
Placebo
Placebo
Intravenous placebo, single dose
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tanezumab
Intravenous, 20 mg, single dose.
Placebo
Intravenous placebo, single dose
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male adults at least 18 years of age
* Moderate to severe chronic prostatitis, with an average pain score above a pre-defined level
* To use contraception.
Exclusion Criteria
* History of recurrent urinary tract infections, or genito-urinary cancer
* Use of finasteride or dutasteride within 6 months.
* History of hepatitis B, C or human immunodeficiency virus (HIV)
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Alabama Research Center, LLC
Birmingham, Alabama, United States
The Kirklin Clinic
Birmingham, Alabama, United States
University of Alabama Birmingham
Birmingham, Alabama, United States
Valley Urologic Associates
Goodyear, Arizona, United States
Dedicated Clinical Research
Litchfield Park, Arizona, United States
Clinical Innovations, Inc.
Costa Mesa, California, United States
Citrus Valley Medical Research Inc.
Glendora, California, United States
Atlantic Urological Medical Group Incorporated
Long Beach, California, United States
Orange Coast Urology
Newport Beach, California, United States
Los Angeles Infertility and Prostatitis Medical Group
Santa Monica, California, United States
Specialists in Urology
Bonita Springs, Florida, United States
Specialists in Urology
Naples, Florida, United States
Pinellas Urology, Inc.
St. Petersburg, Florida, United States
Regional Urology, LLC
Shreveport, Louisiana, United States
Quality Clinical Research
Omaha, Nebraska, United States
Hudson Valley Urology, PC
Kingston, New York, United States
University Urology Associates
New York, New York, United States
Hudson Valley Urology, PC
Poughkeepsie, New York, United States
Tri-State Urologic Services PSC, Inc. dba The Urology Group
Cincinnati, Ohio, United States
Cleveland Clinic
Cleveland, Ohio, United States
Temple University of the Commonwealth System of Higher Education
Philadelphia, Pennsylvania, United States
University Urology
Knoxville, Tennessee, United States
Volunteer Research Group
Knoxville, Tennessee, United States
Prostate Cancer Centre / Urology Research
Calgary, Alberta, Canada
Office of Dr. Nazmuddin Merali
Victoria, British Columbia, Canada
Can-Med Clinical Research Inc.
Victoria, British Columbia, Canada
PJ Pommerville Inc.
Victoria, British Columbia, Canada
Dr. Steinhoff Clinical Research
Victoria, British Columbia, Canada
Manitoba Prostate Centre
Winnipeg, Manitoba, Canada
The Male/Female Health and Research Centre
Barrie, Ontario, Canada
Kingston General Hospital
Kingston, Ontario, Canada
Centre for Applied Urological Research
Kingston, Ontario, Canada
Urology Associates / Urologic Medical Research
Kitchener, Ontario, Canada
The Male Health Centre
Toronto, Ontario, Canada
Royal Victoria Hospital
Montreal, Quebec, Canada
Hopital Edouard Herriot
Lyon, , France
Centre Hospitalier Universitaire de NANTES (CHU)
Nantes, , France
CHU de Nîmes - Hôpital CAREMEAU
Nîmes, , France
Hopital TENON
Paris, , France
Hopital Rothschild
Paris, , France
Capio Citykliniken AB
Lund, , Sweden
Skaraborgs Sjukhus, FoU-centrum och urologkliniken
Skövde, , Sweden
Universitaetsspital Basel, Urologische Klinik
Basel, , Switzerland
Klinik und Poliklinik fuer Urologie, Inselspital
Bern, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2008-004861-25
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
PROSTATITIS POC
Identifier Type: OTHER
Identifier Source: secondary_id
A4091019
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.